- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02976701
Effect of DLBS1033 After Primary PCI in Patients With STE-ACS
The Effect of DLBS1033 in Patients With ST Elevation Acute Coronary Syndrome (STE-ACS) After Primary Percutaneous Coronary Intervention
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
STE-ACS patients who undergo intermediate-delayed (> 3 hours after the onset of the STEMI) primary PCI will be enrolled in the study. Before the intervention, they will be given standard medication for PCI.
Right after PCI, all eligible subjects will be assessed for microvascular perfusion, using a pressure-temperature sensor-tipped coronary guidewire.
The day after, in addition to the dual antiplatelet therapy, i.e. 80 mg aspirin once daily and clopidogrel 75 mg once daily, DLBS1033 at a dose of 980 mg three times daily or its placebo will be given to the subjects for 4 weeks.
Clinical and laboratory examinations to evaluate the investigational drug's efficacy and safety will be performed at Baseline (right after subjects undergo the primary PCI) and at the End of study (week 4th of DLBS1033 therapy).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Muhammad Munawar, SpJP(K), MD
- Phone Number: +62-21-87781605
- Email: muna@cbn.net.id
Study Contact Backup
- Name: Jimmy Agung Pambudi, MD
- Phone Number: +62-21-87781605
- Email: jimmyagung27@gmail.com
Study Locations
-
-
-
Jakarta, Indonesia, 13570
- Binawaluya Cardiac Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
KEY Inclusion Criteria:
- Signed informed consent.
- Men or women of 30-75 years of age.
Evidence of acute ST elevation myocardial infarction (STEMI) at screening, as confirmed by ECG presentation of STEMI: new ST elevation at the J point in two contiguous leads with the cut-points: ≥ 0.1 mV in all leads other than leads V2-V3, where the following cut-points apply: ≥ 0.2 mV in men ≥ 40 years, ≥ 0.25 mV in men < 40 years, or ≥ 0.15 mV in women; or new or presumably new left bundle-branch block (LBBB); and with at least one of the following:
- Positive plasma biomarkers of myocardial necrosis (cardiac troponin I [cTnI]).
- Possible ischaemic symptoms include various combinations of chest, upper extremity, mandibular or epigastric discomfort (with exertion or at rest) or an ischaemic equivalent such as dyspnoea or fatigue.
- The onset of the STEMI is > 3 hours before undergoing the primary PCI.
- Therapy with study medication can be started within 24 hours after primary PCI.
- Able to take oral medication.
KEY Exclusion Criteria:
- Females of childbearing potential: pregnancy, breast-feeding.
- History of hemorrhagic stroke, serious head injury within the last 3 months.
- History of major surgery within the last 6 months.
- History of PCI or CABG, or previous myocardial infarction.
- Ongoing long term need for oral anticoagulants, antiplatelets, fibrinolytic, or antithrombotic agents, other than the study medication.
- Having any implanted pacemaker or cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy defibrillators (CRT-D).
- Present with cardiogenic shock, 3rd degree atrioventricular (AV) block, complex anatomical coronary condition.
- Planned for a staged PCI within 30 days after the current PCI
- Inadequate liver function
- CRUSADE bleeding score of > 30
- Known or suspected allergy to other lumbrokinase products.
- Prior experience with DLBS1033 or other oral lumbrokinase products.
- Clinical evidence of malignancies with survival period < 1 year.
- Any other disease state, including chronic or acute systemic infections, uncontrolled illnesses or other chronic diseases, which judged by the investigator, could jeopardize patient's safety or interfere with trial participation or trial evaluation.
- Subjects enrolled in other interventional protocol within 30 days prior to Screening
- Any other disease state, including chronic or acute systemic infections, uncontrolled illnesses or other chronic diseases, which judged by the investigator, could jeopardize patient's safety or interfere with trial participation or trial evaluation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DLBS1033
DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period
|
Other Names:
Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
Other Names:
|
Placebo Comparator: Placebo
Placebo is administered two tablets three times daily, everyday for four weeks of study period
|
Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Index of microvascular resistance (IMR)
Time Frame: Week 4
|
Improvement in the index of microvascular resistance (IMR) from baseline to week 4th of treatment, measured using the pressure and temperature sensor-tipped guidewire.
|
Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in fractional flow reserve (FFR) from baseline to week 4th of treatment, measured using the pressure and temperature sensor-tipped guidewire
Time Frame: Week 4
|
Improvement in fractional flow reserve (FFR) from baseline and to Week 4th of treatment, measured using the pressure and temperature sensor-tipped guidewire.
|
Week 4
|
LV function
Time Frame: Week 4
|
Improvement in several parameters of left ventricular (LV) function [EF, ESV, EDV], from baseline and to Week 4th of treatment will be measured by 2D echocardiography.
|
Week 4
|
Routine hematology
Time Frame: Week 0 and 4
|
Routine hematology, including: RBC, WBC, and platelet count, will be measured at baseline and week 4th of treatment.
|
Week 0 and 4
|
Routine hematology (Hemoglobin)
Time Frame: Week 0, 2 and 4
|
Hemoglobin will be measured at baseline and every interval of 2 weeks over the 4 weeks of treatment.
|
Week 0, 2 and 4
|
Routine hematology (Hematocrit)
Time Frame: Week 0, 2 and 4
|
Hematocrit will be measured at baseline and every interval of 2 weeks over the 4 weeks of treatment.
|
Week 0, 2 and 4
|
Liver function
Time Frame: Week 0 and 4
|
Liver function measured includes: serum ALT (SGPT), serum AST (SGOT), alkaline phosphatase, and total bilirubin.
|
Week 0 and 4
|
Renal function
Time Frame: Week 0 and 4
|
Renal function measured includes: serum creatinine and BUN.
|
Week 0 and 4
|
Haemostasis parameter (Prothrombin time (PT))
Time Frame: Week 0, 2, and 4
|
Prothrombin time (PT) will be measured at baseline and every interval of 2 weeks over the 4 weeks of study treatment.
|
Week 0, 2, and 4
|
Haemostasis parameter (International Normalized Ratio (INR))
Time Frame: Week 0, 2, and 4
|
International Normalized Ratio (INR) will be measured at baseline and every interval of 2 weeks over the 4 weeks of study treatment.
|
Week 0, 2, and 4
|
Adverse event
Time Frame: Week 0 - 4
|
Adverse events (especially major and minor bleeding) are observed and carefully evaluated along the course of the study.
|
Week 0 - 4
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Muhammad Munawar, SpJP(K), MD, Binawaluya Cardiac Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DLBS1033-0716
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ST Elevation Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Inha University HospitalCompletedST Segment Elevation Myocardial Infarction | Non-ST Segment Elevation Myocardial InfarctionKorea, Republic of
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
RenJi HospitalCompletedST Segment Elevation Myocardial Infarction
-
Dong-A UniversityTerminatedST-Segment Elevation Myocardial InfarctionKorea, Republic of
-
Azienda Ospedaliera San Camillo ForlaniniUnknownST Segment Elevation Myocardial InfarctionItaly
-
Jinan Central HospitalUnknownST-Segment Elevation Myocardial InfarctionChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States